Assessing Regeneron Pharmaceuticals: Insights From 16 Financial Analysts
Assessing Regeneron Pharmaceuticals: Insights From 16 Financial Analysts
评估再生元制药：来自16位金融分析师的见解
Regeneron Pharmaceuticals (NASDAQ:REGN) underwent analysis by 16 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
再生元制药（纳斯达克股票代码：REGN）在上个季度接受了16位分析师的分析，揭示了从看涨到看跌的一系列观点。
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
在下表中，您将找到他们最近的评级摘要，揭示了过去30天中情绪的变化，并将其与前几个月进行了比较。
The 12-month price targets, analyzed by analysts, offer insights with an average target of $1046.81, a high estimate of $1189.00, and a low estimate of $720.00. This current average has increased by 1.92% from the previous average price target of $1027.10.
分析师分析的12个月目标股价提供了见解，平均目标股价为1046.81美元，最高估计为1189.00美元，低估值为720.00美元。目前的平均价格较之前的平均目标价1027.10美元上涨了1.92％。
Investigating Analyst Ratings: An Elaborate Study
调查分析师评级：一项详尽的研究
The analysis of recent analyst actions sheds light on...
对分析师最近行为的...
登录免费看全文
登录/注册